NCT03446261View on ClinicalTrials.gov

Rosuvastatin/Ezetimibe vs Rosuvastatin in Korean Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia

PHASE4CompletedINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

February 23, 2018

Primary Completion Date

March 5, 2019

Study Completion Date

March 5, 2019

Conditions

Type 2 Diabetes MellitusHypercholesterolemia

Interventions

DRUG

Rosuvamibe® Tab

Rosuvastatin 5mg/ezetimibe 10mg qd for 8 weeks

DRUG

Monorova® Tab

Rosuvastatin 10mg qd for 8 weeks

Trial Locations (2)

Unknown

Asan Medical Center, Kora-ri

05505

Asan Medical Center, Seoul

All Listed Sponsors

lead

Yuhan Corporation

INDUSTRY

NCT03446261 - Rosuvastatin/Ezetimibe vs Rosuvastatin in Korean Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia | Biotech Hunter | Biotech Hunter